WallachBeth Capital Announces ABVC BioPharma Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million
Company announcement headlineRead source ↗
Abvc Biopharma, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Fair value per share
Under review: data-quality checks not passed.
Price vs value
Under review: data-quality checks not passed. We'll show the comparison once resolved.
Abvc Biopharma, Inc. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Funds11 adding, 5 cuttingOf 4 active managers that changed their stake, 2 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Gross margin expanding: TTM gross margin reached 99.9%, up 198.0pp year over year.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
- Fast growth. Revenue grew 234.3% over the last 12 months.
- Growth speeding up. The growth rate is 265.4 points higher than a quarter earlier.
- Margins widening. Operating margin is up 3515.9 points on a year ago.
Things to watch
- Loss-making. Operating margin is -923.3%: costs exceed revenue.
- Burning cash. Free cash flow was -355.0% of revenue over the last 12 months.
- Heavy stock-based pay. Stock pay equals 544.3% of revenue: a real cost that cash-flow figures leave out.
- Share dilution. Diluted shares rose 71.7% in a year.
- Volatile shares. Over the past year the shares showed annualised volatility of 86% and a beta of 1.6 against the S&P 500.
- Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.
Latest results: FY2025 Q4
- Earnings per share
- -$0.60 against an average estimate of -$0.50: missed by 20.0%
- Share reaction
- -2.0% in the first session after the results on March 3, 2026, against -0.2% for the S&P 500
Price chart
- 1 day-2.0%
- 1 week-6.7%
- 1 month-3.0%
- This year-54.0%
- 1 year-65.0%
- 5 years-97.6%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- EPS (TTM, diluted)
- $-0.29
Growth
- Share count change
- +71.7%
Cash
- Free cash flow (TTM)
- -$2.7M
Earnings
- Last results
- March 3, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Financing
- Agreement
Abvc Biopharma, Inc. entered a material agreement; ended a material agreement; took on a material financial obligation; sold unregistered shares; reported shareholder vote results; made a public disclosure
SEC 8-KRead source ↗ - Deal
Abvc Biopharma, Inc. entered a material agreement; completed an acquisition or disposal; made a public disclosure
SEC 8-KRead source ↗ - Announcement
Abvc Biopharma, Inc. disclosed a material event
SEC 8-KRead source ↗
Valuation multiples over time Market data may be delayed
| At fiscal year end | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Share price | $360.00 | $43.70 | $51.00 | $33.90 | $6.25 | $1.16 | $0.59 | $2.13 |
| Market value | $428m | $76m | $101m | $85m | $20m | $5m | $7m | $43m |
| + Net debt (− = net cash) | $1m | $3m | −$144208 | −$2m | $2m | $3m | $2m | $74032 |
| Enterprise value | $429m | $80m | $100m | $83m | $22m | $8m | $8m | $43m |
| Multiples | ||||||||
| Price / sales | n/m | 109.0x | n/m | n/m | 20.4x | 33.0x | 13.5x | 144.7x |
| Price / earnings | — | — | — | — | — | — | — | — |
| Price / free cash flow | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
Moat
23 /100
Weak moat
How hard Abvc Biopharma's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Net income has been a median -103.9% of total assets over 10 years.
- Pricing power 12 / 20
Gross margin has been a median 96.6%, moving by 71.7 percentage points (standard deviation) across 6 years.
- Durability 10 / 20
Operating margin has been a median -3290.1%; its worst year was -71457.7%.
- Discipline 0 / 20
The diluted share count rose 2020.8% over five years; stock-based pay has been a median 634.9% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (28 before it).
Forecasts and guidance
Analysts' consensus
No analyst estimates are published for Abvc Biopharma, Inc.: too few analysts cover it.
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Mar 2023 | −$0.50 | −$0.60 | −20.0% |
| Dec 2022 | −$1.50 | −$1.50 | 0.0% |
| Sept 2022 | −$2.00 | −$1.10 | +45.0% |
| Jun 2022 | −$1.25 | −$0.60 | +52.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 2.7% of tradable shares
- Days to cover
- 4.96 at average volume
- Short interest, 1 month
- +17% to October 15, 2026
- Held by institutions
- 4% of shares
- Held by insiders
- 18.1% of shares
- Employees
- 16 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| ABVC | −34% | −82% | −81% | −49% | +261% | −54% |
| Industry peers (median) | −36% | −56% | −17% | −28% | −5% | −26% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| ABVC | 42% | 25% | 33% | 50% | 58% | 36% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| ABVC | −64% | −86% | −92% | −76% | −57% | −70% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 100% from November 2, 2015 to February 13, 2025. Getting back needed a 341934% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $0.71 – $2.99
- From 52-week high
- −67.2%
- vs 50-day average
- −1.4%
- vs 200-day average
- −21.7%
- Volatility (1 year)
- 86%
- Beta vs S&P 500
- 1.64
Share price after results
- Next day
- 5 up, 7 down typical move ±7.8%
- After a week
- 7 up, 5 down typical move ±13.9%
- After a month
- 4 up, 8 down typical move ±19.9%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| March 3, 2026 | −2.0% | −0.2% | −1.4% | −27.0% |
| November 3, 2025 | +0.7% | −1.0% | +1.8% | −8.2% |
| August 14, 2025 | +11.1% | −0.2% | +2.4% | −3.4% |
| May 1, 2025 | −0.9% | +2.2% | +24.5% | +45.3% |
| April 15, 2025 | +5.4% | −2.5% | −4.8% | +31.5% |
| November 14, 2024 | −6.5% | −1.9% | +2.8% | −4.7% |
| August 15, 2024 | −12.1% | +1.9% | −5.3% | −9.9% |
| March 14, 2024 | −4.9% | −0.9% | −13.8% | −11.4% |
| November 15, 2023 | +42.0% | +0.3% | +67.0% | +16.1% |
| July 24, 2023 | 0.0% | +0.7% | −34.5% | −48.4% |
| March 31, 2023 | +3.5% | +1.8% | +7.6% | +17.7% |
| March 31, 2022 | −4.2% | −1.3% | +1.1% | −15.4% |
Fundamentals
Source: SEC EDGAR filings. Retrieved November 1, 2026.
View chart data
| Period | Revenue (TTM) |
|---|---|
| FY22 Q1 | $118.3K |
| FY22 Q2 | $399.7K |
| FY22 Q3 | $343K |
| FY22 Q4 | $969.8K |
| FY23 Q1 | $1.1M |
| FY23 Q2 | $765.6K |
| FY23 Q3 | $739.3K |
| FY23 Q4 | $152.4K |
| FY24 Q1 | $25.4K |
| FY24 Q2 | $136.4K |
| FY24 Q3 | $509.8K |
| FY24 Q4 | $509.6K |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
View chart data
| Period | Revenue growth, TTM YoY |
|---|---|
| FY22 Q1 | -82.3% |
| FY22 Q2 | -15.4% |
| FY22 Q3 | -24.7% |
| FY22 Q4 | 172.6% |
| FY23 Q1 | 806.5% |
| FY23 Q2 | 91.5% |
| FY23 Q3 | 115.5% |
| FY23 Q4 | -84.3% |
| FY24 Q1 | -97.6% |
| FY24 Q2 | -82.2% |
| FY24 Q3 | -31.0% |
| FY24 Q4 | 234.3% |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
View chart data
| Period | Operating margin (TTM) |
|---|---|
| FY22 Q1 | -14092.1% |
| FY22 Q2 | -4173.7% |
| FY22 Q3 | -5372.8% |
| FY22 Q4 | -1558.5% |
| FY23 Q1 | -1007.3% |
| FY23 Q2 | -1430.0% |
| FY23 Q3 | -1269.9% |
| FY23 Q4 | -4439.2% |
| FY24 Q1 | -30354.5% |
| FY24 Q2 | -4666.6% |
| FY24 Q3 | -885.2% |
| FY24 Q4 | -923.3% |
Source: SEC EDGAR filings. Retrieved November 1, 2026.
View chart data
| Period | FCF margin (TTM) |
|---|---|
| FY13 Q2 | -1694.3% |
| FY13 Q3 | -485.0% |
| FY22 Q3 | -2793.5% |
| FY22 Q4 | -775.2% |
| FY23 Q1 | -550.3% |
| FY23 Q2 | -440.4% |
| FY23 Q3 | -570.5% |
| FY23 Q4 | -2746.7% |
| FY24 Q1 | -14371.5% |
| FY24 Q2 | -2167.7% |
| FY24 Q3 | -301.6% |
| FY24 Q4 | -355.0% |
Financial statements
| Fiscal year | 2010 Sept 2010 | 2011 Sept 2011 | 2012 Sept 2012 | 2013 Sept 2013 | 2014 Sept 2014 | 2015 Dec 2015 | 2018 Dec 2018 | 2019 Dec 2019 | 2020 Dec 2020 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | ||||||||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 50 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 |
| Gross profit | — | — | — | — | 0 | — | −0 | 1 | 0 | 0 | 1 | −0 | 1 | — |
| EBITDA | −2 | −2 | −1 | −0 | — | — | −3 | −3 | −8 | −12 | −15 | −7 | −5 | −7 |
| Operating income | −2 | −2 | −1 | −0 | — | — | −3 | −3 | −9 | −12 | −15 | −7 | −5 | −7 |
| Net income | −2 | −1 | −1 | −0 | −0 | — | −6 | −4 | −11 | −13 | −16 | −8 | −5 | −8 |
| Diluted EPS | −$70500.00 | −$46500.00 | −$18000.00 | $0.00 | −$1.80 | — | −$3.60 | −$0.21 | −$0.50 | −$0.51 | −$5.19 | −$1.80 | −$0.42 | −$0.39 |
| Growth (year on year) | ||||||||||||||
| Revenue | — | −78.5% | +79.1% | +36.3% | −100.0% | — | −100.0% | +>999% | −31.2% | −26.3% | +172.6% | −84.3% | +234.3% | −41.9% |
| Margins | ||||||||||||||
| Gross margin | — | — | — | — | — | — | <−999% | 97.1% | 96.1% | 98.6% | 70.5% | −98.1% | 99.9% | — |
| EBITDA margin | <−999% | <−999% | <−999% | <−999% | — | — | <−999% | −485.1% | <−999% | <−999% | <−999% | <−999% | −917.1% | <−999% |
| Operating margin | <−999% | <−999% | <−999% | <−999% | — | — | <−999% | −492.9% | <−999% | <−999% | <−999% | <−999% | −923.3% | <−999% |
| Net margin | <−999% | <−999% | <−999% | <−999% | — | — | <−999% | −560.5% | <−999% | <−999% | <−999% | <−999% | −962.1% | <−999% |
| Free-cash-flow margin | <−999% | <−999% | <−999% | −485.0% | — | — | — | — | — | <−999% | −775.2% | <−999% | −355.0% | <−999% |
| Cash flow | ||||||||||||||
| Cash from operations | −1 | −2 | −1 | −0 | 0 | — | −1 | −3 | −5 | −8 | −7 | −4 | −2 | −3 |
| Capital spending | −0 | 0 | 0 | 0 | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −1 | −2 | −1 | −0 | — | — | — | — | — | −8 | −8 | −4 | −2 | −3 |
| Stock-based pay | — | — | — | — | — | — | 0 | 0 | 4 | 5 | 7 | 0 | 3 | 4 |
| Free cash flow after stock pay | — | — | — | — | — | — | — | — | — | −13 | −15 | −4 | −5 | −7 |
| Balance sheet | ||||||||||||||
| Cash | — | — | — | — | — | 0 | 0 | 0 | 4 | 6 | 0 | 0 | 0 | 1 |
| Total debt | 1 | 0 | 0 | 0 | — | 0 | 1 | 3 | 4 | 4 | 2 | 3 | 2 | 1 |
| Net debt (negative = net cash) | — | — | — | — | — | −0 | 1 | 3 | −0 | −2 | 2 | 3 | 2 | 0 |
| Diluted shares | 44m | 65m | 64m | 61m | 62m | — | 1m | 2m | 2m | 3m | 3m | 4m | 12m | 20m |
| Quarter | 2023 Q3 Sept 2023 | 2023 Q4 Dec 2023 | 2024 Q1 Mar 2024 | 2024 Q2 Jun 2024 | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 16 | 2 | 1 | 117 | 389 | 2 | 796 | −500 |
| Gross profit | −14 | −137 | 1 | 117 | 389 | 2 | 796 | — |
| EBITDA | −2,147 | −504 | −2,837 | −847 | −295 | −694 | −1,959 | −2,193 |
| Operating income | −2,155 | −512 | −2,838 | −860 | −302 | −705 | −1,964 | −2,199 |
| Net income | −3,318 | −383 | −2,834 | −942 | −395 | −732 | −2,042 | −2,767 |
| Diluted EPS | −$0.82 | $0.28 | −$0.29 | −$0.08 | −$0.03 | −$0.05 | −$0.09 | −$0.11 |
| Growth (year on year) | ||||||||
| Revenue | −62.4% | −99.6% | −99.1% | +>999% | +>999% | −9.2% | +104.5% | <−999% |
| Margins | ||||||||
| Gross margin | −86.4% | <−999% | 77.0% | 99.8% | 99.9% | 100.0% | 100.0% | — |
| EBITDA margin | <−999% | <−999% | <−999% | −722.9% | −75.9% | <−999% | −246.1% | 438.7% |
| Operating margin | <−999% | <−999% | <−999% | −734.2% | −77.7% | <−999% | −246.8% | 439.8% |
| Net margin | <−999% | <−999% | <−999% | −804.4% | −101.4% | <−999% | −256.6% | 553.5% |
| Free-cash-flow margin | — | <−999% | — | −180.5% | 15.5% | <−999% | −121.2% | 117.5% |
| Cash flow | ||||||||
| Cash from operations | −1,359 | −430 | −956 | −211 | 60 | −702 | −965 | −588 |
| Capital spending | — | 0 | — | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | — | −430 | — | −211 | 60 | −702 | −965 | −588 |
| Stock-based pay | 818 | −1,224 | 2,032 | 283 | 96 | 363 | 1,136 | 1,386 |
| Free cash flow after stock pay | — | 794 | — | −494 | −36 | −1,065 | −2,101 | −1,974 |
Financial health
- Short-term assets cover short-term liabilities $411,729 of assets due within a year against $6m of liabilities due within a year.
- Short-term assets cover long-term liabilities $411,729 short-term assets against $1m of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Operating income of −$7m against $155,210 of interest.
Dividends, buybacks and capital spending
- Diluted share count
- +71.7%
- year over year
Competitors: side by side with peers
| Last 12 months unless stated | ABVC | CRDF | CRVO | MNOV | STTK | LGVN | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $509589 | $508000 | $331295 | $920481 | $1m | $1m | $55m |
| Revenue growth, last 12 months | 234.3% | −7.0% | −95.7% | 875.7% | −66.6% | −42.7% | 12.7% |
| Revenue growth, 3-year average | 12.7% | 7.2% | −52.7% | — | 5.2% | 10.4% | 13.1% |
| Revenue growth, latest quarter | 104.5% | −14.0% | −100.0% | 240.6% | −66.6% | −9.2% | 10.2% |
| Gross margin | 99.9% | 100.0% | 100.0% | 100.0% | — | 69.8% | 82.9% |
| Operating margin | −923.3% | <−999% | <−999% | <−999% | <−999% | <−999% | −191.1% |
| Operating margin, 3-year average | <−999% | <−999% | <−999% | −905.8% | <−999% | <−999% | −365.3% |
| Net margin | −962.1% | <−999% | <−999% | <−999% | <−999% | <−999% | −172.8% |
| Cash from operations / revenue | −355.0% | <−999% | <−999% | −989.7% | <−999% | <−999% | −168.8% |
| Free-cash-flow margin | −355.0% | <−999% | — | −991.2% | <−999% | <−999% | −168.1% |
| Free-cash-flow margin, 3-year average | <−999% | <−999% | — | <−999% | <−999% | <−999% | −313.4% |
| Stock pay / revenue | 544.3% | >999% | 393.0% | 100.3% | 853.2% | 132.8% | 20.7% |
| Change in share count | 71.7% | 15.8% | 8.4% | 0.2% | 15.3% | — | 8.3% |
Who owns it
Funds buying and selling- Reported value
- $1.7M
- Institutions reporting
- 14
- Shares held vs prior quarter
- ▲ 33.5%
- Positions opened / closed
- 7 / 5
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Vanguard Capital Management LLC | $591,708 | 374K | 34.4% | ▲ 96.5% |
| Geode Capital Management, LLC | $360,380 | 228K | 20.9% | ▲ 3.1% |
| Vanguard Fiduciary Trust Co | $153,834 | 97K | 8.9% | 0.0% |
| State Street Corp | $115,024 | 73K | 6.7% | 0.0% |
| Citadel Advisors LLC | $113,904 | 72K | 6.6% | New |
| Blackrock, Inc. | $89,178 | 56K | 5.2% | 0.0% |
| Northern Trust Corp | $76,856 | 49K | 4.5% | ▲ 51.6% |
| Xtx Topco Ltd | $76,276 | 48K | 4.4% | New |
| Panagora Asset Management Inc | $57,958 | 37K | 3.4% | New |
| UBS Group AG | $53,914 | 34K | 3.1% | ▲ 1826.8% |
| Jane Street Group, LLC | $31,693 | 20K | 1.8% | New |
| Citigroup Inc | $853 | 1K | 0.0% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Abvc Biopharma, Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
- March 3, 2026
- November 3, 2025
- August 14, 2025
- May 1, 2025
- April 15, 2025
- November 14, 2024
Recent SEC filings
- 8-K Current report
- DEF 14A Proxy statement
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Abvc Biopharma, Inc. in brief
- What does Abvc Biopharma, Inc. do?
- Abvc Biopharma, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Abvc Biopharma, Inc.'s stock ticker?
- Abvc Biopharma, Inc. trades under the ticker ABVC on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Abvc Biopharma, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Vanguard Capital Management LLC, Geode Capital Management, LLC and Vanguard Fiduciary Trust Co. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- What is Abvc Biopharma, Inc.'s market cap?
- On December 31, 2025, Abvc Biopharma, Inc.'s market capitalisation was about $42.8M and net debt of $74,032. Market figures come from third-party market data and may be delayed.
- Who are Abvc Biopharma, Inc.'s competitors?
- In our Biotechnology peer group, the companies closest to Abvc Biopharma, Inc. are Cardiff Oncology, Inc., Cervomed Inc., Medicinova Inc, Shattuck Labs, Inc. and Longeveron Inc. The side-by-side comparison below sets their revenue, margins and growth against Abvc Biopharma, Inc.'s.
Follow research on Abvc Biopharma, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.